Sartorius Stedim Biotech (CHIX:DIMP) Policy Acquisition Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
82 GF Score
Price €184.45
GF Value €202.63
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

CHIX:DIMP
82GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Policy Acquisition Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €184.45 is trading 9% below its estimated GF Value™ of €202.63. GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.

Key valuation signals for CHIX:DIMP:

  • Policy Acquisition Expense:
  • GF Value™: €202.63 vs. price of €184.45 (9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech SA is a French-German supplier of bioprocessing equipment and consumables used to develop and manufacture biologic drugs, vaccines, and cell and gene therapies. Its portfolio covers fermentation and cell culture, filtration, fluid management, purification and chromatography, and cell culture media, with a strong emphasis on single-use technologies that replace stainless-steel systems. Customers are primarily biopharmaceutical manufacturers, contract development and manufacturing organizations, and research laboratories. The company operates through two segments, Bioprocess Solutions and Lab Products & Services, and generates revenue mainly from recurring sales of consumables, filters, bags, and resins, supplemented by equipment and service contracts. It sells globally across the Americas, Europe, the Middle East and Africa, and Asia-Pacific, including China. Sartorius Stedim Biotech is majority-owned and consolidated by Sartorius AG, which holds most of its shares and voting rights.
82GF Score

Get the complete analysis for CHIX:DIMP

Policy Acquisition Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€184.45
Price
€202.63
GF Value